Cooperation of IRAK1/4 inhibitor and ABT-737 in nanoparticles for synergistic therapy of T cell acute lymphoblastic leukemia

Xiaoyan Wu,1 Lin Wang,1 Yining Qiu,1 Bingyu Zhang,1 Zhenhua Hu,2 Runming Jin1 1Department of Pediatrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 2Department of Pharmacy, Shanghai Jiao Tong University, Shanghai, China Abstract: T cell acute lymp...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Wu X, Wang L, Qiu Y, Zhang B, Hu Z, Jin R
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	T-cell acute lymphoblastic leukemia IRAK1/4 inhibitor ABT-737 Box-Behnken design and response surface methodology PEG-PLGA Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/306041da56814dcbbe83f900c4bce877
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:306041da56814dcbbe83f900c4bce877
record_format	dspace
spelling	oai:doaj.org-article:306041da56814dcbbe83f900c4bce8772021-12-02T07:22:51ZCooperation of IRAK1/4 inhibitor and ABT-737 in nanoparticles for synergistic therapy of T cell acute lymphoblastic leukemia1178-2013https://doaj.org/article/306041da56814dcbbe83f900c4bce8772017-10-01T00:00:00Zhttps://www.dovepress.com/cooperation-of-irak14-inhibitor-and-abt-737-in-nanoparticles-for-syner-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Xiaoyan Wu,1 Lin Wang,1 Yining Qiu,1 Bingyu Zhang,1 Zhenhua Hu,2 Runming Jin1 1Department of Pediatrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 2Department of Pharmacy, Shanghai Jiao Tong University, Shanghai, China Abstract: T cell acute lymphoblastic leukemia (T-ALL) is caused by clonal expansion of variant T cell progenitors and is considered as a high risk leukemia. Contemporary single chemotherapy has a limited effect due to dynamic and versatile properties of T-ALL. Here IRAK1/4 inhibitor and ABT-737 were co-encapsulated into polyethylene glycol modified poly (lactic-co-glycolic acid) nanoparticles (IRAK/ABT-NP) to enhance synergistic therapy of T-ALL. The formulation was optimized to achieve high drug loading using Box-Behnken design and response surface methodology. The optimal parameter comprised 2.98% polymer in acetonitrile, a ratio of oil phase to water phase of 1:8.33, and 2.12% emulsifier concentration. High drug loading and uniform spherical shape was achieved. In vitro release study showed sustained release of IRAK1/4 inhibitor for 72 hours as well as sustained release of ABT-737 for more than 120 hours. Uptake efficiency of IRAK/ABT-NP and induced apoptotic T-ALL fraction by IRAK/ABT-NP were much higher than the IRAK1/4 and ABT-737 combined solution. IC50 of IRAK/ABT-NP was two-fold lower than free drug combination in Jurkat cells. Additionally, we conducted in vivo experiments in which IRAK/ABT-NP exhibited greater cytotoxicity toward T-ALL cells, the capacity to significantly restore white blood cell number in peripheral blood, and improved survival time of T-ALL mouse model compared to the IRAK1/4 and ABT-737 combined solution. Keywords: T cell acute lymphoblastic leukemia, IRAK1/4 inhibitor, ABT-737, Box-Behnken design and response surface methodology, PEG-PLGAWu XWang LQiu YZhang BHu ZJin RDove Medical PressarticleT-cell acute lymphoblastic leukemiaIRAK1/4 inhibitorABT-737Box-Behnken design and response surface methodologyPEG-PLGAMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 12, Pp 8025-8034 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	T-cell acute lymphoblastic leukemia IRAK1/4 inhibitor ABT-737 Box-Behnken design and response surface methodology PEG-PLGA Medicine (General) R5-920
spellingShingle	T-cell acute lymphoblastic leukemia IRAK1/4 inhibitor ABT-737 Box-Behnken design and response surface methodology PEG-PLGA Medicine (General) R5-920 Wu X Wang L Qiu Y Zhang B Hu Z Jin R Cooperation of IRAK1/4 inhibitor and ABT-737 in nanoparticles for synergistic therapy of T cell acute lymphoblastic leukemia
description	Xiaoyan Wu,1 Lin Wang,1 Yining Qiu,1 Bingyu Zhang,1 Zhenhua Hu,2 Runming Jin1 1Department of Pediatrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 2Department of Pharmacy, Shanghai Jiao Tong University, Shanghai, China Abstract: T cell acute lymphoblastic leukemia (T-ALL) is caused by clonal expansion of variant T cell progenitors and is considered as a high risk leukemia. Contemporary single chemotherapy has a limited effect due to dynamic and versatile properties of T-ALL. Here IRAK1/4 inhibitor and ABT-737 were co-encapsulated into polyethylene glycol modified poly (lactic-co-glycolic acid) nanoparticles (IRAK/ABT-NP) to enhance synergistic therapy of T-ALL. The formulation was optimized to achieve high drug loading using Box-Behnken design and response surface methodology. The optimal parameter comprised 2.98% polymer in acetonitrile, a ratio of oil phase to water phase of 1:8.33, and 2.12% emulsifier concentration. High drug loading and uniform spherical shape was achieved. In vitro release study showed sustained release of IRAK1/4 inhibitor for 72 hours as well as sustained release of ABT-737 for more than 120 hours. Uptake efficiency of IRAK/ABT-NP and induced apoptotic T-ALL fraction by IRAK/ABT-NP were much higher than the IRAK1/4 and ABT-737 combined solution. IC50 of IRAK/ABT-NP was two-fold lower than free drug combination in Jurkat cells. Additionally, we conducted in vivo experiments in which IRAK/ABT-NP exhibited greater cytotoxicity toward T-ALL cells, the capacity to significantly restore white blood cell number in peripheral blood, and improved survival time of T-ALL mouse model compared to the IRAK1/4 and ABT-737 combined solution. Keywords: T cell acute lymphoblastic leukemia, IRAK1/4 inhibitor, ABT-737, Box-Behnken design and response surface methodology, PEG-PLGA
format	article
author	Wu X Wang L Qiu Y Zhang B Hu Z Jin R
author_facet	Wu X Wang L Qiu Y Zhang B Hu Z Jin R
author_sort	Wu X
title	Cooperation of IRAK1/4 inhibitor and ABT-737 in nanoparticles for synergistic therapy of T cell acute lymphoblastic leukemia
title_short	Cooperation of IRAK1/4 inhibitor and ABT-737 in nanoparticles for synergistic therapy of T cell acute lymphoblastic leukemia
title_full	Cooperation of IRAK1/4 inhibitor and ABT-737 in nanoparticles for synergistic therapy of T cell acute lymphoblastic leukemia
title_fullStr	Cooperation of IRAK1/4 inhibitor and ABT-737 in nanoparticles for synergistic therapy of T cell acute lymphoblastic leukemia
title_full_unstemmed	Cooperation of IRAK1/4 inhibitor and ABT-737 in nanoparticles for synergistic therapy of T cell acute lymphoblastic leukemia
title_sort	cooperation of irak1/4 inhibitor and abt-737 in nanoparticles for synergistic therapy of t cell acute lymphoblastic leukemia
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/306041da56814dcbbe83f900c4bce877
work_keys_str_mv	AT wux cooperationofirak14inhibitorandabt737innanoparticlesforsynergistictherapyoftcellacutelymphoblasticleukemia AT wangl cooperationofirak14inhibitorandabt737innanoparticlesforsynergistictherapyoftcellacutelymphoblasticleukemia AT qiuy cooperationofirak14inhibitorandabt737innanoparticlesforsynergistictherapyoftcellacutelymphoblasticleukemia AT zhangb cooperationofirak14inhibitorandabt737innanoparticlesforsynergistictherapyoftcellacutelymphoblasticleukemia AT huz cooperationofirak14inhibitorandabt737innanoparticlesforsynergistictherapyoftcellacutelymphoblasticleukemia AT jinr cooperationofirak14inhibitorandabt737innanoparticlesforsynergistictherapyoftcellacutelymphoblasticleukemia
_version_	1718399448995856384

Cooperation of IRAK1/4 inhibitor and ABT-737 in nanoparticles for synergistic therapy of T cell acute lymphoblastic leukemia

Ejemplares similares